Source: Streetwise Reports   04/22/2020

In an April 19 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that the Biomedical Advanced Research and Development Authority (BARDA) awarded Moderna Inc. (MRNA:NASDAQ) $483 million in funding, in part for development of its COVID-19 vaccine, mRNA-1273.

Rahimi discussed how Massachusetts-based Moderna will use the funds, which will be provided in tranches to reach certain milestones.

Half of the $483 million award will be used to help cover clinical development costs of mRNA-1273, from trial operations to the filing of a biologics license application.

Currently, the vaccine is in Phase 1 in the clinic. Recently, the biopharma decided to add to the study a cohort of patients aged 51 years and up, which "will be key for demonstrating mRNA-1273's safety and immunogenicity in this vulnerable population," Rahimi noted.

The analyst explained that for mRNA-1273 to advance to Phase 2, the results from Phase 1 must be optimal. The data must demonstrate the vaccine is safe and tolerable. They must show that the vaccine produced a sufficient number of neutralizing antibodies, crucial for stopping viral replication and proving the vaccine's method of action. Phase 1 safety data from the group aged 18–55 years are expected in spring followed by immunogenicity results, likely in mid-July or early August.

Rahimi relayed that as soon as safety data are available, Moderna plans to launch a Phase 2 study of mRNA-1273 rather than wait for the remaining results to become available, according to CEO Stéphane Bancel.

"Pending favorable safety data from Phase 1, we point out that a potential Phase 2 study would enroll hundreds of patients, and that the BARDA funding could potentially allow Moderna to pursue trials in patient populations who are at greater risk, such as patients who have underlying comorbidities, those who are overweight and patients with cancer," commented Rahimi.

Moderna will spend the second half of the $483 million BARDA funding on the engineering and optimization work required to scale up the manufacturing of its messenger RNA (mRNA).

"With the current focus on SARS-CoV-2 and mRNA-1273, Moderna was now able to present BARDA its strategic plans (amount, time and people) of how to be ready for commercial launch," wrote Rahimi. "This preparation was likely helpful in expediting discussions with BARDA and awarding of the grant."

Also regarding mRNA production, Ginkgo Bioworks, a company with expertise in organism biology and genetically engineering bacteria to replace certain industrial applications, is helping Moderna optimize certain parts of the process.

Rahimi, who is closely tracking COVID-19 data, highlighted that April 18 was the first day in five on which the daily death tally, 1,867, was less than that predicted by Dr. Christopher Murray's model, 2,194.

ROTH has a Buy rating on Moderna.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, Moderna Inc., Company Note, April 19, 2020

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Within the last twelve months, ROTH has received compensation for investment banking services from Moderna, Inc.

ROTH makes a market in shares of Moderna, Inc. and as such, buys and sells from customers on a principal basis.

Within the last twelve months, ROTH has managed or co-managed a public offering for Moderna, Inc.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

( Companies Mentioned: MRNA:NASDAQ, )

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

Farber Cancer Institute investigators report they have discovered a type of immune antibody that can rapidly evolve to neutralize a wide array of influenza virus strains - including those the body hasn't yet encountered.

read more

Spanish medical and public health researchers have found no clear evidence for increased heavy metal levels in adults living near a recently-built urban solid waste incinerator over two years of operation. Concentrations of lead, chromium and mercury in blood and urine samples taken around the plant were not significantly higher than for populations who lived further away.

Italian researchers have demonstrated low-cost techniques which may transform fly ash produced by Municipal Solid Waste Incineration from hazardous landfill into potentially the world's fifth largest raw material resource. The initial results have prompted European Commission funding for a demonstration project under LIFE+.

From driving behavioral change to encouraging doctor-patient collaboration, telemedicine’s time in the sun has proved beneficial as a collateral benefit of Covid-19.

The NABH Digital Health Standards aims to consider all relevant aspects of the application of patient interfacing technologies across the continuum of care applicable for outpatient, inpatient, and remote patient monitoring.

The use of nanomaterials in consumer goods is growing, as is their presence in waste. A new study is the first to follow the fate of engineered nanoparticles through the entire waste incineration chain. The results indicate current filter technology is effective in removing nanoparticles from flue gas, but that nanoparticles also bind to residues, such as fly ash and slag, which eventually end up in landfill.

Ash from waste incineration can be made safer simply by mixing it with rice husks, water and other forms of waste ash at temperatures under 100 °C, according to new research. Once dried, the end product not only locks away toxic metals lead and zinc, but also stores carbon. Furthermore, it can be used in the polymer industry to lower costs, improve polymer properties and reduce the use of natural resources.

Phosphorus can be extracted in viable quantities from fly ash, a by-product created when municipal solid waste is burnt in incinerators, according to research conducted in Sweden. Sufficient phosphorus could be recovered from the country’s incinerators to meet 30% of the Swedish annual demand for mineral fertilisers, say the researchers.

Advances in nanotechnology mean that a rapidly increasing number of products are being produced using engineered nanomaterials, for example, nano-enabled thermoplastics. Many of these nano-enabled products are destined to reach their end-of-life through waste incineration or accidental fire. Now, an original study has revealed that the presence of nanofiller in thermoplastics significantly enhances both the concentration and toxicity of polycyclic aromatic hydrocarbons (PAHs) produced during thermal decomposition at the product’s end- of-life, resulting in concentrations of total PAHs and more toxic PAHs that are up to eight times higher than those found in pure (non nano-enabled) thermoplastics. This finding has significant environmental health implications.

Ultrafine particles emitted from a waste incinerator plant in Italy have been characterised in a recent study. The results suggest that a fabric filter was efficient at cleaning particulate matter from the exhaust gases. Data produced by the study could go on to be used by scientists studying the potential health impacts of ultrafine particles.

Recently adopted EU waste legislation and its implementation at national level could have a significant effect on some countries’ emission loads for municipal solid waste incinerators, according to a recent study. The study suggests that the effects of increasing incineration over the next decade would be most profound for countries where incineration is currently only used on a small scale.

Emissions from well-regulated household waste incinerators do not reduce the quality of vegetables and milk produced nearby, a Dutch study suggests. Researchers found that levels of certain contaminants were similar whether vegetables and milk came from the area surrounding three incinerators, or from elsewhere in the Netherlands. They say biomonitoring programmes could offer a way to increase the understanding of the real impacts of waste incineration and to improve communication between waste management companies and local communities.

Fifth-year students at the NTU Lee Kong Chian School of Medicine have started on SimConsult - a simulated clinical training - after postings to hospitals were suspended due to the Covid-19 outbreak....

After 'Exclusion Day,' kids in Oregon without completed vaccination paperwork are sent home from school until the problem is solved.

The number of teenage girls and boys in the United States who have received the vaccine remains "unacceptably low" says the CDC.

Health experts argue that banning the preservative could make it difficult for children in developing countries to get life-saving vaccines.

There's more to energy medicine than acupuncture. Here's how to get an energizing workout in only 10 minutes.

Bees that ate the immune-boosting chemicals showed activation in genes known to help them fight parasites and break down pesticides.

New research could stop the spread of citrus greening, a disease that is killing Florida's oranges.

Human trials are set to begin on the treatment, which cured 100 percent of mice during animal trials.

Developed at the University of Helsinki, PrimeBEE allows immunological signals to be passed from a queen bee to her offspring.

The rotavirus vaccine may also have the unexpected advantage of reducing rates of Type 1 diabetes.

Black women's contributions to society have often been overlooked, yet these pioneers in science, technology and medicine have changed history.

Breakthrough vaccine technique makes you immune to all forms of the flu virus.

New survey finds that 40 percent of parents disregard warning labels and give cough and cold medicine to young kids.

Could H1N1 have a bright side? New research leads to encouraging steps forward in the fight against flu.

The new process may provide a revolutionary, all-purpose flu vaccine.

Despite the report, the CDC still advises older people to get a flu shot.

Twitter posts with anti-vaccine sentiments are "contagious," while posts with a positive take on vaccines are not.

Although the rise in cases of the H7N9 bird flu in China seems to have slowed, health officials are developing a vaccine against the virus.

Getting a flu shot may reduce the risk of major heart problems, such as heart attacks or unexpected chest pain.

Women have a stronger immune response than men when given the flu vaccine.

The Centers for Disease Control and Prevention says that the nasal spray form of the flu vaccine is the preferred way to vaccinate kids ages 2 to 8.

Research centers collaborate to create a better, longer-lasting solution to the yearly flu assault.

Want to Make Medicines Greener? It’s in the Chemistry

Alternative medicine and modern medicine have may differences and whose to say which is best? This article explores the roots of alternative medicine and compares it's healing style to that of modern medicine

Read the latest Medical articles from ArticleGeek.com

Generic medications, exactly what the doctor ordered. More and more Americans are choosing Generic Pharmacies to maintain their quality of life. Read on!

Dr. McNair utilizes her medical expertise as a general practitioner as well as in LGBT activism

Boston BioLife will be hosting a workshop and lecture event for regenerative medicine this November 17th, 18th, and 19th at the Hilton San Diego Resort & Spa in San Diego, California.

Dr. Mora specializes in allergy and immunology with the Chicago Allergy Center

Independent filmmaker seeks funding through Kickstarter to complete documentary about spiritual leader

Dr. Yaratha provides decades of expertise to his current positions with Gateway Homes and in private practice

Behavioral Health Provider Fills Growing Need in Georgia with Telehealth Appointments

Dr. Stuart D. Shoengold, of Millburn, New Jersey, is recognized by the International Association of Who's Who with the Albert Einstein Award of Medicine for his extensive contributions within the field of Urology.

Dr. Julia Caldwell, M.D., of Bowling Green, Kentucky has been recognized by the International Association of Who's Who for exemplary achievements in the fields of Pain Medicine and Anesthesiology.

Dr. Sayegh channels years of expertise into his work as a surgeon and physician consultant